Biomarkers and risk factors for the early prediction of immune-related adverse events: a review

Biomarkers and risk factors for the early prediction of immune-related adverse events: a review

In recent years, immunotherapy has been widely used to treat patients with malignant tumors. While immune checkpoint inhibitors (ICIs) significantly improve the prognosis of cancer patients, the incidence of immune-related adverse events (irAEs) is increasing. Not only can irAEs accumulate in multip...

Full description

Bibliographic Details
Main Authors: Ying Zhang, Xiaoling Zhang, Weiling Li, Yunyi Du, Wenqing Hu, Jun Zhao
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
immune checkpoint inhibitors
immune-related adverse events
early prediction
biomarkers
risk factors
Online Access:http://dx.doi.org/10.1080/21645515.2021.2018894

Internet

http://dx.doi.org/10.1080/21645515.2021.2018894

Similar Items